

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7525181

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HORIZON PHARMA RHEUMATOLOGY LLC	03/31/2020
RECEIVING PARTY DATA	
Name:	HORIZON THERAPEUTICS USA, INC.
Street Address:	150 SOUTH SAUNDERS ROAD
City:	LAKE FOREST
State/Country:	ILLINOIS
Postal Code:	60045
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15649478
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2028427800
Email:	zIPatentDocketingMailboxUS@cooley.com, jaclyn.torres@cooley.com
Correspondent Name:	COOLEY LLP ATTN: PATENT GROUP
Address Line 1:	1299 PENNSYLVANIA AVENUE, NW
Address Line 2:	SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	308248-2746
NAME OF SUBMITTER:	DAVID A. SCHACHTER
SIGNATURE:	/David Schachter/
DATE SIGNED:	09/07/2022
Total Attachments: 24	
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page1.tif	
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page2.tif	
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page3.tif	
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page4.tif	

source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page5.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page6.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page7.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page8.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page9.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page10.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page11.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page12.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page13.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page14.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page15.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page16.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page17.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page18.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page19.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page20.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page21.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page22.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page23.tif
source=Horizon - IP Assignment (HTUSA and Rheumatology) (002)#page24.tif

INTELLECTUAL PROPERTY ASSIGNMENT

This **INTELLECTUAL PROPERTY ASSIGNMENT** (the “Assignment”), effective as of March 31, 2020 (the “Effective Date”), is between **HORIZON THERAPEUTICS USA, INC.**, a Delaware corporation with its principal place of business located at 150 South Saunders Road, Lake Forest, Illinois 60045 (“Assignee”), and **HORIZON PHARMA RHEUMATOLOGY LLC**, a Delaware limited liability company with its principal place of business located at 150 South Saunders Road, Lake Forest, Illinois 60045 (“Assignor”). Assignee and Assignor are sometimes referred to herein individually as a “party” and collectively as the “parties.”

WHEREAS, pursuant to that certain Agreement and Plan of Merger, dated as of March 31, 2020 (as it may be amended, restated or otherwise modified from time to time, the “Merger Agreement”), by and between Assignee and Assignor, the parties thereto have agreed to effect the merger of Assignor with and into Assignee, with Assignee as the surviving entity in such merger, upon the terms and subject to the conditions set forth in the Merger Agreement;

WHEREAS, pursuant to Article VI, Section A of the Merger Agreement, this Assignment will be duly executed and delivered by Assignor to Assignee; and

WHEREAS, Assignor is willing to assign all rights it may have in and to all Transferred IP (as defined below) and the goodwill associated with such Transferred IP on the terms and subject to the conditions set forth in this Assignment.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by Assignor and Assignee, Assignor and Assignee agree as follows:

1. Definitions.

(a) “Entity” means any corporation (including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity.

(b) “Governmental Body” means any: (i) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (ii) federal, state, local, municipal, foreign or other government or (ii) governmental or quasi-governmental authority of any nature including any governmental division, department, agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court, arbitrator or other tribunal.

(c) “Patents” means patents (including utility, utility model, plant and design patents, and certificates of invention), patent applications (including additions, provisional, national, regional and international applications, as well as original, continuation, continuation-in-part, divisionals, continued prosecution applications, reissues, and re-examination applications), patent or invention disclosures, registrations, applications for registrations and any term extension or other action by a Governmental Body which provides rights beyond the original expiration date of any of the foregoing.

(d) “Trademark” means any word, name, symbol, color, product shape, designation or device or any combination thereof that functions as a source identifier, including any trademark, trade dress, brand mark, service mark, trade name, brand name, product configuration, logo or business symbol, whether or not registered, and including applications for registrations.

2. Assignment. Effective as of the Effective Date, Assignor hereby irrevocably sells, transfers, conveys, assigns and delivers to Assignee, its successors and assigns, all of Assignor’s right, title and interest in and to all of the following (collectively, the “Transferred IP”):

- (a) all rights of Assignor under the Patents identified on **EXHIBIT A**;
- (b) all rights of Assignor under the Trademarks identified on **EXHIBIT B**; and
- (c) all copyrights and domain names.

3. Authorization. Assignor authorizes and requests the applicable Governmental Bodies in any applicable jurisdictions, whose duty is to issue patents, trademarks or copyrights applications as aforesaid, to issue the same to Assignee and to record Assignee as owner of the Transferred IP, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.

4. Further Assurances. Assignor shall provide Assignee, its successors and assigns with all such assistance as it may reasonably request for the full utilization of the rights to the Transferred IP granted in Section 2 above.

5. Miscellaneous.

(a) Controlling Agreement. This Assignment is executed and delivered pursuant to, is in accordance with, and is subject to, the provisions set forth in the Merger Agreement, all of which shall survive the consummation of the transactions contemplated hereby on the basis and to the extent set forth in the Merger Agreement. In the event that any provision of this Assignment shall be construed to conflict with a provision in the Merger Agreement, the provision in the Merger Agreement shall control.

(b) Governing Law. To the fullest extent permitted by law, this Assignment shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to principles of conflict of laws.

(c) Severability. If any provision of this Assignment is held to be illegal, invalid or unenforceable under any present or future law, and if the rights or obligations of either party under this Assignment will not be materially and adversely affected thereby, (i) such provision shall be fully severable, (ii) this Assignment shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (iii) the remaining provisions of this Assignment shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (iv) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this

Assignment a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the parties.

(d) Waiver. Any term or condition of this Assignment may be waived at any time by the party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such term or condition. The waiver by either party of any right hereunder or of the failure to perform or of a breach by the other party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other party whether of a similar nature or otherwise.

(e) Amendments. This Assignment may not be amended, modified, altered or supplemented except by means of a written instrument executed on behalf of all parties.

(f) Counterparts. This Assignment may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this Assignment by portable document format (PDF) or other electronic transmission shall be effective as delivery of a manually executed original counterpart of this Assignment.


(g) Binding Agreement. This Assignment shall be binding on and inure to the benefit of Assignee and Assignor and their respective successors and assigns.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned have executed this Intellectual Property Assignment on and as of the date first indicated above.

ASSIGNEE:

HORIZON THERAPEUTICS USA, INC.

By: 
Name: Paul Hoelscher
Title: EVP, Chief Financial Officer

ASSIGNOR:

HORIZON PHARMA RHEUMATOLOGY LLC

By: _____
Name: Timothy Walbert
Title: President, Chief Executive Officer

IN WITNESS WHEREOF, the undersigned have executed this Intellectual Property Assignment on and as of the date first indicated above.

ASSIGNEE:

HORIZON THERAPEUTICS USA, INC.

By: _____
Name: Paul Hoelscher
Title: EVP, Chief Financial Officer

ASSIGNOR:

HORIZON PHARMA RHEUMATOLOGY LLC


By:  _____
Name: Timothy Walbert
Title: President, Chief Executive Officer

EXHIBIT A
TRANSFERRED PATENTS

Product	Country	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	China (People's Republic)	201780082380.X	11/10/2017			Published	COMBINATION THERAPIES OF PREDNISONONE AND URICASE MOLECULES AND USES THEREOF	Horizon Pharma Rheumatology, LLC	11/10/2037
KRYSTEXXA	European Patent Convention	17869608.4	11/10/2017			Published	COMBINATION THERAPIES OF PREDNISONONE AND URICASE MOLECULES AND USES THEREOF	Horizon Pharma Rheumatology, LLC	11/10/2037
KRYSTEXXA	Hong Kong	62020002320	2/6/2020			Pending	COMBINATION THERAPIES OF PREDNISONONE AND URICASE MOLECULES AND USES THEREOF	Horizon Pharma Rheumatology, LLC	11/10/2037
KRYSTEXXA	Japan	2019-546771	11/10/2017			Pending	COMBINATION THERAPIES OF PREDNISONONE AND URICASE MOLECULES AND USES THEREOF	Horizon Pharma Rheumatology, LLC	11/10/2037
KRYSTEXXA	United States of America	16/347,900	5/7/2019			Pending	COMBINATION THERAPIES OF PREDNISONONE AND URICASE MOLECULES AND USES THEREOF		11/10/2037
KRYSTEXXA	Australia	2010265964	6/25/2010	2010265964	1/8/2015	Granted	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGLOTICASE THERAPY	Ceralta Pharmaceuticals LLC	6/25/2030
KRYSTEXXA	Canada	2,766,309	6/25/2010			Published	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGLOTICASE THERAPY	Ceralta Pharmaceuticals LLC	
KRYSTEXXA	European Patent Convention	18214393.3	12/20/2018			Published	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGLOTICASE THERAPY	Horizon Pharma Rheumatology, LLC	6/25/2030

Product	County	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Hong Kong	19130474	10/3/2019			Pending	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGLOTTICASE THERAPY	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	Israel	216956	6/25/2010	216956	2/1/2017	Granted	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGLOTTICASE THERAPY	Creatia Pharmaceuticals LLC	6/25/2030
KRYSTEXXA	Korea, Republic of	10-2011-7031627	6/25/2010	10-1861547	5/21/2018	Granted	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGLOTTICASE THERAPY	Creatia Pharmaceuticals LLC	6/25/2030
KRYSTEXXA	United States of America	13/379,704	6/25/2010	9,377,454	6/28/2016	Granted	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGLOTTICASE THERAPY	Horizon Pharma Rheumatology, LLC	6/25/2030
KRYSTEXXA	United States of America	16/195,446	11/19/2018			Published	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGLOTTICASE THERAPY	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	United States of America	15/906,839	2/27/2018	10,139,399	11/27/2018	Granted	METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGLOTTICASE THERAPY	Horizon Pharma Rheumatology, LLC	6/25/2030
KRYSTEXXA	United States of America	11/539,475	10/6/2006	8,148,123	4/3/2012	Granted	METHODS FOR LOWERING ELEVATED URIC ACID LEVELS USING INTRAVENOUS INJECTIONS OF PEG-URICASE	Horizon Pharma Rheumatology-Duke University	9/8/2027
KRYSTEXXA	Taiwan	95112937	4/11/2006	1366467	6/21/2012	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026

Product	Country	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	United States of America	11/918,297	4/11/2006	8,188,224	5/29/2012	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	13/972,167	8/21/2013	9,017,980	4/28/2015	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	14/671,246	3/27/2015	9,670,467	6/6/2017	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	16/202,743	11/28/2018			Published	VARIANT FORMS OF URATE OXIDASE USE THEREOF	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	United States of America	13/461,170	5/1/2012	8,541,205	9/24/2013	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	15/649,462	7/13/2017	9,926,537	3/27/2018	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	15/649,478	7/13/2017	10,160,958	12/25/2018	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	15/649,488	7/13/2017	9,926,538	3/27/2018	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	Australia	2006235495	4/11/2006	2006235495	7/26/2012	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	China (People's Republic)	200680021018.3	4/11/2006	ZL 2006800210183	3/27/2013	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	European Patent Convention	6749889.9	4/11/2006	1871874	4/8/2015	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Germany	122015000081.9	10/6/2015			Published	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	1/10/2028
KRYSTEXXA	Spain	C201530058	10/5/2015	C201530058	1/20/2017	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	1/10/2028
KRYSTEXXA	France	15C0067	10/7/2015	209253	2/12/2016	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	1/10/2028
KRYSTEXXA	United Kingdom	SPC/GB15/062	10/6/2015			Pending	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	1/9/2028
KRYSTEXXA	Hungary	S1300039	8/14/2013			Pending	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	Italy	193232	10/8/2015	1484	2/29/2016	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	1/8/2028

Product	County	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Poland	DPO.0246				Pending	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	1/8/2028
KRYSTEXXA	European Patent Convention	17192971.4	4/11/2006			Published	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	Hong Kong	8106827.8	4/11/2006	1112021	1/22/2016	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Israel	186510	4/11/2006	186510	6/25/2013	Granted	ISOLATED TRUNCATED MAMMALIAN URICASE COMPRISING AN AMINO ACID SUBSTITUTION AT POSITION 46, THE SAID TRUNCATION AND AMINO ACID SUBSTITUTION BEING RELATIVE TO A NATURALLY OCCURRING PIG URICASE	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Japan	2016-132216	4/11/2006			LAPSE	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	
KRYSTEXXA	Japan	2019-000199	4/11/2006			Published	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	
KRYSTEXXA	Poland	P-387691	4/11/2006	215285	5/22/2013	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Switzerland	6749889.9	4/11/2006	1871874	4/8/2015	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Germany	6749889.9	4/11/2006	1871874	4/8/2015	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Spain	6749889.9	4/11/2006	2538357	4/8/2015	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	France	6749889.9	4/11/2006	1871874	4/8/2015	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	United Kingdom	6749889.9	4/11/2006	1871874	4/8/2015	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Hungary	P0700730	4/11/2006	229068		Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Italy	6749889.9	4/11/2006	1871874	4/8/2015	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Turkey	6749889.9	4/11/2006	TR 2015 05340 T4	4/8/2015	Granted	VARIANT FORMS OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026

Product	Country	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	United States of America	11/918,296	4/11/2006	7,811,800	10/12/2010	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	13/107,498	5/13/2011	8,034,594	10/11/2011	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	13/226,891	9/7/2011	8,178,334	5/15/2012	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	13/452,151	4/20/2012	8,293,228	10/23/2012	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	13/623,512	9/20/2012	8,465,735	6/18/2013	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	United States of America	12/879,084	9/10/2010	7,964,381	6/21/2011	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Horizon Pharma Rheumatology, LLC	4/11/2026
KRYSTEXXA	Australia	2006235437	4/11/2006	2006235437	3/8/2012	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Australia	2011257764	4/11/2006	2011257764	7/19/2012	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	China (People's Republic)	200680020689, 8	4/11/2006	ZL 2006800206898	9/5/2012	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Eastman Kodak Company	4/11/2026
KRYSTEXXA	European Patent Convention	14192835, 8	4/11/2006	2918676	1/31/2018	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Hungary	P0700729	4/11/2006	229626	2/17/2014	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Israel	186511	4/11/2006	186511	4/1/2013	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Israel	208643	4/11/2006	208643	12/1/2012	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Israel	223476	4/11/2006	223476	4/1/2018	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Israel	223477	4/11/2006	223477	2/1/2018	Granted	PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED URICASE	Creatia Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Israel	256157	4/11/2006			Pending	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	
KRYSTEXXA	India	3808/KOLNP/2007	4/11/2006	268092	8/17/2015	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Creatia Pharmaceuticals LLC	4/11/2026

Product	County	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Korea, Republic of	10-2007-7026114	4/11/2006	1304289	8/30/2013	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Mexico	MX/A/2007/012548	4/11/2006	293490	12/9/2011	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Mexico	MX/A/2011/013255	4/11/2006	297727	4/2/2012	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	New Zealand	562291	4/11/2006	562291	6/10/2010	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Poland	P-384263	4/11/2006	215157	4/8/2013	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Poland	DPO.0247				Pending	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Russian Federation	2007141683	4/11/2006	2435847	12/10/2011	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Singapore	201002408-1	4/11/2006	161248	5/26/2014	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Singapore	2014009484	4/11/2006	2014009484	8/29/2017	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Singapore	10201706384V	4/11/2006			Published	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	South Africa	2007/08651	4/11/2006	2007/08651	3/31/2010	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Germany	14192835.8	4/11/2006	2918676	1/31/2018	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	France	14192835.8	4/11/2006	2918676	1/31/2018	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	United Kingdom	14192835.8	4/11/2006	2918676	1/31/2018	Granted	VARIANT FORM OF URATE OXIDASE AND USE THEREOF	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	Taiwan	95112938	4/11/2006	1418564	12/11/2013	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/11/2026
KRYSTEXXA	United States of America	11/918,292	4/12/2006	9,534,013	1/3/2017	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Horizon Pharma Rheumatology, LLC	9/10/2027

Product	Country	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	United States of America	16/455,073	6/27/2019			Published	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	
KRYSTEXXA	Australia	2006339865	4/12/2006	2006339865	4/26/2012	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	China (People's Republic)	200680021020	4/12/2006	ZL 2006800210200	1/1/2014	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	European Patent Convention	6749952.5	4/12/2006	2013225	12/17/2014	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Hong Kong	9105691.2	4/12/2006	1126794	10/23/2015	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Hungary	P0800388	4/12/2006	230 758	1/31/2018	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Israel	186514	10/9/2007	186514	1/30/2016	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Japan	2009-505340	4/12/2006	5033177	7/6/2012	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Korea, Republic of	10-2007-7025066	4/12/2006	10-1288027	7/15/2013	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Switzerland	6749952.5	4/12/2006	2013225	12/17/2014	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Czech Republic	PV2007-701	4/12/2006		4/13/2016	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Germany	6749952.5	4/12/2006	2013225	12/17/2014	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Spain	6749952.5	4/12/2006	2013225	12/17/2014	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	France	6749952.5	4/12/2006	2013225	12/17/2014	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	United Kingdom	6749952.5	4/12/2006	2013225	12/17/2014	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Italy	6749952.5	4/12/2006	2013225	12/17/2014	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Crealta Pharmaceuticals LLC	4/12/2026

PATENT

REEL: 061389 FRAME: 0576

Product	County	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Poland	6749952.5	4/12/2006	2013225	12/17/2014	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Creatia Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Turkey	6749952.5	4/12/2006	TR 2015 02488 T4	12/17/2014	Granted	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT	Creatia Pharmaceuticals LLC	4/12/2026
KRYSTEXXA	Brazil	PI9912974-4	8/2/1999	PI9912974-4	8/25/2015	Granted	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	Mountain View Pharmaceuticals / Duke University	8/25/2025
KRYSTEXXA	Brazil	PI9917760-9	8/2/1999	PI 9917760-9	11/25/2014	Granted	METHOD FOR ISOLATING A TETRAMERIC FORM FROM A SOLUTION OF PURIFIED URICASE	Mountain View Pharmaceuticals / Duke University	
KRYSTEXXA	Czech Republic	PV2001-317	8/2/1999	303751	3/13/2013	Granted	URICASE PHARMACEUTICAL COMPOSITION, MEDICAMENT, USE AND PROCESS FOR PREPARING THEREOF	Mountain View Pharmaceuticals / Duke University	8/2/2019
KRYSTEXXA	Czech Republic	SPC/CZ2013-280	7/2/2013	303751/280	7/19/2018	Granted	URICASE PHARMACEUTICAL COMPOSITION, MEDICAMENT, USE AND PROCESS FOR PREPARING THEREOF	Mountain View Pharmaceuticals / Duke University	8/2/2024
KRYSTEXXA	Israel	141220	8/2/1999	141220	12/21/2007	Granted	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	Mountain View Pharmaceuticals / Duke University	8/2/2019
KRYSTEXXA	Israel	183948	8/2/1999	183948	3/1/2011	Granted	PEG-URATE OXIDASE CONJUGATES AND USE THEREOF	Mountain View Pharmaceuticals / Duke University	8/2/2019
KRYSTEXXA	United States of America	11/357,028	2/21/2006			Published	URATE OXIDASE	Duke University	
KRYSTEXXA	Brazil	PI9913360-1	8/5/1999	PI9913360-1	9/24/2013	Granted	URATE OXIDASE	Duke University	9/24/2023
KRYSTEXXA	Israel	141221	8/5/1999	141221	9/17/2010	Granted	URATE OXIDASE	Duke University	8/5/2019
KRYSTEXXA	Israel	197339	8/5/1999	197339	5/27/2015	Granted	RECOMBINANT URICASE PROTEIN	Duke University	8/5/2019
KRYSTEXXA	United States of America	09/501,730	2/10/2000	6,783,965	8/31/2004	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Horizon Pharma Rheumatology-Duke University	7/21/2023
KRYSTEXXA	Taiwan	90102540	2/6/2001	1322184	3/21/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/6/2021

Product	County	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Australia	2006203252	2/7/2001	2006203252	1/21/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Australia	2009212900	2/7/2001	2009212900	3/22/2012	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Brazil	P10108386-4	2/7/2001	P1 0108386-4	10/31/2017	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	10/31/2027
KRYSTEXXA	Brazil	C10108386-4	2/7/2001			Published	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	
KRYSTEXXA	Canada	2,398,679	2/7/2001	2398679	11/17/2015	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	China (People's Republic)	1807750.1	2/7/2001	ZL 018077501	5/27/2009	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	China (People's Republic)	200910127853	2/7/2001	ZL 2009101278530	9/11/2013	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Czech Republic	2002-2982	2/7/2001	304864	11/5/2014	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	European Patent Convention	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Austria	SZ41/2013	2/7/2001	41/2013	1/18/2016	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2026
KRYSTEXXA	Belgium	2013C/045	7/3/2013			Pending	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	
KRYSTEXXA	Cyprus, Republic of	2013028	2/7/2001	CY2013028	6/11/2015	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2026

Product	County	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Germany	1220130000589	7/5/2013	12 2013 000 058	10/22/2019	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2026
KRYSTEXXA	Denmark	CA201300038	7/5/2013	CA201300038	7/5/2015	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2026
KRYSTEXXA	Spain	C300096380	2/7/2001	C201330007	7/11/2014	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2026
KRYSTEXXA	Finland	C20130035	2/7/2001	538	10/4/2018	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2026
KRYSTEXXA	France	13C0036	7/4/2013	13C0036	5/16/2014	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2026
KRYSTEXXA	United Kingdom	SPC/GB13/039	6/27/2013	1254237	2/7/2021	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/6/2026
KRYSTEXXA	Greece	20130800034	7/8/2013	800496	3/31/2015	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/8/2026
KRYSTEXXA	Hungary	S1300029	7/4/2013			Pending	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	
KRYSTEXXA	Italy	UB2013CCCP001310	2/7/2001	UB2013CCCP001310	10/28/2013	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2026
KRYSTEXXA	Luxembourg	92237	7/3/2013	92237	9/3/2014	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2026
KRYSTEXXA	Netherlands	300601	7/8/2013	300601	5/21/2015	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/6/2026
KRYSTEXXA	Poland	DPO.0239	7/5/2013			Pending	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	

Product	Country	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Portugal	549	7/8/2013	2014-549	4/4/2014	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER	Mountain View Pharmaceuticals / Duke University	2/7/2026
KRYSTEXXA	Sweden	1390031-1	2/7/2001	1390031-1	5/26/2014	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2026
KRYSTEXXA	European Patent Convention	10158016.5	2/7/2001	2196538	10/1/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	European Patent Convention	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Hong Kong	3109064.9	2/7/2001	1056742B	11/27/2009	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Hong Kong	10111402.7	2/7/2001	HK1144701	6/6/2014	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Hong Kong	10110105.9	2/7/2001	HK1143989	8/14/2015	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Hong Kong	11109405.7	2/7/2001	HK1155203	9/25/2015	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Israel	151065	2/7/2001	151065	3/30/2009	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Israel	151065	8/5/2002			Published	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	7/21/2023
KRYSTEXXA	Israel	193365	2/7/2001	193365	12/1/2011	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	India	IN/PCT/2002/983/KOL		226519	12/17/2008	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021

Product	County	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Japan	2001-558218	2/7/2001	5165826	12/28/2012	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Japan	2011-088663	2/7/2001	5341945	8/16/2013	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Korea, Republic of	7010189/2002	2/7/2001	10-0884724	2/13/2009	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Korea, Republic of	10-2008-7024272	2/7/2001	10-1054247	7/29/2011	Granted	PURIFIED URATE OXIDASE PREPARATION, COMPOSITION COMPRISING THE SAME, AND PURIFYING METHOD THEREOF	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Mexico	PA/A/2002/007545	2/7/2001	233192	12/20/2005	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Mexico	PA/A/2005/013892	2/7/2001	279587	9/29/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	New Zealand	520434	2/7/2001	520434	9/9/2004	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Poland	P-358539	2/7/2001	208064	11/5/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Russian Federation	2002120486	2/7/2001	2281954	8/20/2006	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Russian Federation	2006107110	2/7/2001	2352354	4/20/2009	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Russian Federation	2009104003	2/7/2001	2557318	6/24/2015	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Singapore	200204601-9	2/7/2001	90846	11/30/2004	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021

Product	County	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	South Africa	2002/7/206	2/7/2001	2002/7/206	7/30/2003	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Austria	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Austria	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Belgium	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Belgium	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Switzerland	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Switzerland	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Cyprus, Republic of	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Cyprus, Republic of	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Germany	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Germany	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Denmark	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021

Product	County	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Denmark	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Spain	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Spain	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Finland	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Finland	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	France	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	France	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	United Kingdom	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	United Kingdom	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Greece	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Greece	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Hungary	P0204544	2/7/2001	227127	5/21/2015	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021

Product	County	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Italy	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Italy	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Luxembourg	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Luxembourg	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Monaco	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Monaco	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Netherlands	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Netherlands	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Portugal	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Portugal	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Sweden	1923265.1	2/7/2001	1254237	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Sweden	10180428.4	2/7/2001	2305819	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021

Product	Country	App. No.	Filing Date	Patent No.	Issue Date	App Status	Title	Registered Owner	Expiration Date
KRYSTEXXA	Turkey	1923265.1	2/7/2001	TR 2010 03973 T4	4/7/2010	Granted	AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	Turkey	10180428.4	2/7/2001	TR 2014 14825 T4	11/12/2014	Granted	CONJUGATES PREPARED WITH AGGREGATE-FREE PROTEINS	Mountain View Pharmaceuticals / Duke University	2/7/2021
KRYSTEXXA	United States of America	62/903,562	9/20/2019			Pending	TOLERIZATION REDUCES INTOLERANCE TO PEGLOTICASE AND PROLONGS THE URATE LOWERING EFFECT (TRIPLE)	Horizon Pharma Rheumatology, LLC	9/20/2020
KRYSTEXXA	United States of America	16/777,625	1/30/2020			Pending	TOLERIZATION REDUCES INTOLERANCE TO PEGLOTICASE AND PROLONGS THE URATE LOWERING EFFECT (TRIPLE)	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	Patent Cooperation Treaty	PCT/US2020/015956	1/30/2020			Pending	TOLERIZATION REDUCES INTOLERANCE TO PEGLOTICASE AND PROLONGS THE URATE LOWERING EFFECT (TRIPLE)	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	United States of America	62/903,567	9/20/2019			Pending	REDUCING IMMUNOGENICITY TO PEGLOTICASE	Horizon Pharma Rheumatology, LLC	9/20/2020
KRYSTEXXA	United States of America	16/777,634	1/30/2020			Pending	REDUCING IMMUNOGENICITY TO PEGLOTICASE	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	Patent Cooperation Treaty	PCT/US2020/015958	1/30/2020			Pending	REDUCING IMMUNOGENICITY TO PEGLOTICASE	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	United States of America	62/855,519	5/31/2019			Pending	REDUCING IMMUNOGENICITY TO PEGLOTICASE		5/31/2020
KRYSTEXXA	United States of America	62/903,570	9/20/2019			Pending	REDUCING IMMUNOGENICITY TO PEGLOTICASE	Horizon Pharma Rheumatology, LLC	9/20/2020
KRYSTEXXA	United States of America	16/777,646	1/30/2020			Pending	REDUCING IMMUNOGENICITY TO PEGLOTICASE	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	Patent Cooperation Treaty	PCT/US2020/015959	1/30/2020			Pending	REDUCING IMMUNOGENICITY TO PEGLOTICASE	Horizon Pharma Rheumatology, LLC	
KRYSTEXXA	United States of America	62/894,452	8/30/2019			Pending	PEGLOTICASE FOR TREATMENT OF GOUT IN RENAL TRANSPLANT	Horizon Pharma Rheumatology, LLC	8/30/2020

EXHIBIT B

TRANSFERRED TRADEMARKS

Mark/Name	Country / Region	Case Type	Filing Type	Status	Registered Owner	Current App. Date	Current App. No.	Current Registration Date	Current Registration Number	Current Renewal Date
CREALTA	United States - (US)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	9/18/2013	86/977,046	10/13/2015	4,883,793	10/13/2025
CREALTA PHARMACEUTICALS	United States - (US)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	9/18/2013	86/976,925	9/29/2015	4,823,992	9/29/2025
EVOLUTION OF GOUT	United States - (US)	Intent-To-Use - (Z)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	9/14/2018	88/117,954	11/12/2019	5909837	11/12/2029
GOUT EXXCHANG E	Canada - (CA)	Regular - (REG)	National - (NAT)	Filed - (F)	Horizon Pharma Rheumatology LLC - (126635)	6/8/2017	1841662			
GOUT EXXCHANG E	United States - (US)	Intent-To-Use - (Z)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	12/9/2016	87/264,067	5/1/2018	5,459,980	5/1/2028
KRYSTEXXA	West Bank - (WBAN)	Regular - (REG)	National - (NAT)	Docket - (D)						1/15/2024
KRYSTEXXA	Russian Federation - (RU)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	2/19/2009	2009703192	3/29/2010	404873	2/19/2029
KRYSTEXXA	South Africa - (ZA)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC - (126635)	8/11/2011	2011/19724	10/25/2013	2011/19724	8/11/2021
KRYSTEXXA	Liechtenstein - (LI)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC - (126635)	9/21/2011	2011-883	9/21/2011	16178	9/21/2021
KRYSTEXXA	Switzerland - (CH)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC - (126635)	8/22/2011	59558/2011	12/23/2011	624135	8/22/2021
KRYSTEXXA	Singapore - (SG)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	2/18/2009	T0901651F	2/18/2009	T0901651F	2/18/2029

Mark/Name	Country / Region	Case Type	Filing Type	Status	Registered Owner	Current App. Date	Current App. No.	Current Registration Date	Current Registration Number	Current Renewal Date
KRYSTEXXA	Taiwan - (TW)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC <small>(126635 Crealta)</small>	2/23/2010	099007982	9/16/2010	1429142	9/15/2020
KRYSTEXXA	United States - (US)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	8/21/2008	77552516	2/15/2011	3,920,201	2/15/2021
KRYSTEXXA	Argentina - (AR)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC <small>(126635 Crealta)</small>	11/2/2011	3126226	5/15/2015	2726635	5/15/2025
KRYSTEXXA	Australia - (AU)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	2/16/2009	1285184	2/16/2009	1285184	2/16/2029
KRYSTEXXA	Israel - (IL)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC <small>(126635 Crealta)</small>	8/10/2011	239854	12/4/2012	239854	8/10/2021
KRYSTEXXA	Japan - (JP)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	2/18/2009	2009-011005	11/13/2009	5280562	11/13/2019
KRYSTEXXA	Korea, Republic of (South) - (KR)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC <small>(126635 Crealta)</small>	2/18/2009	40-2009-0007322	9/3/2009	40-0799893	9/3/2029
KRYSTEXXA	Canada - (CA)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	5/4/2016	1780693	8/16/2019	1,049,647	8/16/2029
KRYSTEXXA	China P.R. - (CN)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC <small>(126635 Crealta)</small>	2/20/2009	7209501	8/21/2010	7209501	8/20/2020
KRYSTEXXA	Hong Kong - (HK)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	2/16/2009	301287469	2/16/2009	301287469	2/15/2029
KRYSTEXXA	India - (IN)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	2/19/2009	1787489	12/6/2012	1787489	2/19/2029
KRYSTEXXA	Monaco - (MC)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC <small>(126635 Crealta)</small>	6/3/2011	30233	7/8/2011	11,28612	6/3/2021
KRYSTEXXA	Brazil - (BR)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC <small>(126635 Crealta)</small>	2/17/2009	830193189	2/7/2012	830193189	2/7/2022

Mark/Name	Country / Region	Case Type	Filing Type	Status	Registered Owner	Current App. Date	Current App. No.	Current Registration Date	Current Registration Number	Current Renewal Date
KRYSTEXXA	Community Trademark - (EM)	Regular - (REG)	Community Trademark Convention - (C)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	2/18/2009	008110967	10/12/2009	008110967	2/18/2029
KRYSTEXXA	New Zealand - (NZ)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	2/16/2009	802548	8/20/2009	802548	2/16/2029
KRYSTEXXA	Mexico - (MX)	Regular - (REG)	National - (NAT)	Registered - (G)	Crealta Pharmaceuticals LLC <small>(126635, Crealita)</small>	2/17/2009	990227	4/7/2009	1093461	2/17/2029
KRYSTEXXA PEGLOTICASE K & Design	United States - (US)	Intent-To-Use - (Z)	National - (NAT)	Filed - (F)	Horizon Pharma Rheumatology LLC - (126635)	1/11/2017	87297,485			
KRYSTEXXA PEGLOTICASE K & Design	Canada - (CA)	Regular - (REG)	National - (NAT)	Registered - (G)	Horizon Pharma Rheumatology LLC - (126635)	7/14/2017	1847514	8/16/2019	1,049,645	8/16/2029

PATENT

REEL: 061389 FRAME: 0588

RECORDED: 09/07/2022